SCHEMBL14804153

SCHEMBL14804153

CCc1ccc(OCCNC(=O)OC(C)(C)C)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
IDO1 P14902 3/20 0.46
AAK1 Q2M2I8 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 1/20 0.44
CSNK2A1 P68400 2/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
SLC5A1 P13866 1/20 0.42
PPARD Q03181 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9165272 0.86 IDO1 (0.50) CA12CA1CA2CA9IDO1
SCHEMBL3453194 0.86 IDO1 (0.60) CA12CA1CA2CA9IDO1
SCHEMBL21601440 0.85 AAK1 (0.49) CA12CA1CA2CA9IDO1
SCHEMBL18591140 0.84 CA1 (0.50) CA12CA1CA2CA9IDO1
SCHEMBL21601370 0.84 SCN9A (0.48) CA12CA1CA2CA9IDO1
SCHEMBL16584974 0.84 AAK1 (0.62) CA12CA1CA2CA9IDO1
SCHEMBL4007583 0.84 CA12 (0.50) CA12CA1CA2CA9IDO1
SCHEMBL13166235 0.84 KDM4E (0.46) CA12CA1CA2CA9IDO1
SCHEMBL28624037 0.83 SMN1; SMN2 (0.47) CA12CA1CA2CA9IDO1
SCHEMBL14660487 0.82 TP53 (0.57) CA12CA1CA2CA9IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765764-B2 2-acylaminothiazole derivative or salt thereof ASTELLAS PHARMA, INC. (JP) 2014-07-01 US disclosed
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA, INC. (JP) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079351-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF MPL, JAK2, ABL1 CA12 3808/4885CA1 4612/4885CA2 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.